The association will urge drugmakers to adopt the following three practices:
- Include suggested retail prices in direct-to-consumer drug ads
- Give advanced warning of any prices increase surpassing 10 percent annually
- Highlight price increases for the opioid overdose antidote naloxone
“Taken together, these policies would bring much needed transparency to drug pricing and provide a clear benefit to consumers struggling with exorbitant costs,” Barbara McAneny, MD, president-elect of the AMA’s Chicago-based chapter, said in a Thursday news release. “There seems to be no logic — or warning — to these price spikes.”
Holly Campbell, a spokeswoman for Pharmaceutical Research and Manufacturers of America — a major drug industry lobby group — opposes the AMA’s recommendations.
“The proposal to include the list price of a medicine on an ad would provide no meaningful benefit to patients,” Ms. Campbell told Chicago Tribune Thursday via email. “Price comparison websites already exist to help consumers compare and look for the best retail prices, the price the consumer actually pays, for their medications at local pharmacies. Disclosure of list price information on an advertisement would not help patients gain meaningful access to their medicines.”
More articles on supply chain:
Nevada governor signs drug price transparency legislation: 5 things to know
Hospira recalls several injectables over sterility concerns
Trump administration readies executive order addressing drug prices
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
